Less than nine months after submitting the relevant application to the Food and Drug Administration (FDA), the neuroscience technology Company has announced the receipt of clearance to market its CANTAB Mobile product as a medical device in the U.S. CANTAB Mobile is designed to detect clinicallyrelevant memory impairment in older adults at the point of care. Being classified as a European Medical Device in 2013, CANTAB Mobile has been used routinely to assess over 26k patients in the UK (prim
26 Jan 2017
CANTAB Mobile cleared for marketing in the U.S.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CANTAB Mobile cleared for marketing in the U.S.
Cambridge Cognition Holdings Plc (COG:LON) | 52.0 0 0.0% | Mkt Cap: 18.3m
- Published:
26 Jan 2017 -
Author:
Derren Nathan -
Pages:
6
Less than nine months after submitting the relevant application to the Food and Drug Administration (FDA), the neuroscience technology Company has announced the receipt of clearance to market its CANTAB Mobile product as a medical device in the U.S. CANTAB Mobile is designed to detect clinicallyrelevant memory impairment in older adults at the point of care. Being classified as a European Medical Device in 2013, CANTAB Mobile has been used routinely to assess over 26k patients in the UK (prim